What is Tenax Therapeutics, Inc. (TENX) stock price today?

Tenax Therapeutics, Inc. (TENX) is currently trading at $1.83, down 2.14% today.

What is TENX P/E ratio?

Tenax Therapeutics, Inc.'s P/E ratio is -1.33. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is TENX return on equity (ROE)?

Tenax Therapeutics, Inc.'s return on equity (ROE) is -61.55%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Tenax Therapeutics, Inc.'s market cap?

Tenax Therapeutics, Inc. has a market capitalization of $48.54M.

NASDAQ · Biotechnology

Tenax Therapeutics, Inc. (TENX) Stock

$1.83 -2.14% NASDAQ: TENX Healthcare

Valuation

Metric	Value
Price	$1.83
Market Cap	$48.54M
P/E Ratio	-1.33
P/B Ratio	0.89
P/S Ratio	0.00
EPS (TTM)	$-1.34
52-Week High	$19.40
52-Week Low	$1.31
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-61.55%
ROA	-53.31%
ROCE	-60.40%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	14.86

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-33.0M	$-11.0M	$-8.0M	$-19.0M	$-56.0M
Net Profit	$-32.0M	$-11.0M	$-8.0M	$-18.0M	$-53.0M
EPS	$-2524.80	$-600.80	$-31.04	$-1.15	$-1.34
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$6.0M	$3.0M	$12.0M	$97.0M	$104.0M
Total Liabilities	$2.0M	$2.0M	$4.0M	$5.0M	$7.0M
Cash	$6.0M	$2.0M	$10.0M	$95.0M	$98.0M
Borrowings	$0	$1.0M	$1.0M	$0	$0

Latest News

Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know Zacks · Jul 21, 2026 Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June MT Newswires · Jul 2, 2026 Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 GlobeNewswire · Jul 2, 2026 Chardan Initiates Tenax Therapeutics at Buy MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-11.0M	$-12.0M	$-6.0M	$-15.0M	$-36.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$1.0M	$0	$0	$0	$0
Net Cash Flow	$-1.0M	$-3.0M	$8.0M	$85.0M	$3.0M
Free Cash Flow	$-11.0M	$-12.0M	$-6.0M	$-15.0M	$-36.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.03
EV / EBITDA	0.99
FCF Yield	-87.64%
Quick Ratio	15.07
Interest Coverage	0.00
Return 1Y	141.82%
Return 3Y	-42.81%
Return 5Y	-99.48%

Ownership

Insiders Held0.15%

Institutions Held75.77%

Institutions Float Held75.89%

Institutional Holder	Shares	Report Date
Price (T.Rowe) Associates Inc	2,951,116	2026-03-31
Janus Henderson Group PLC	1,815,474	2026-03-31
Venrock Adviser, LLC	1,675,262	2026-03-31
Perceptive Advisors Llc	1,447,782	2026-03-31
Ikarian Capital, LLC	1,017,600	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$340.97	+1.29%	38.93	$5.01T	0.32%
MSFTMicrosoft Corporation	$541.15	+1.14%	28.68	$4.02T	0.76%
GOOGLAlphabet Inc.	$352.72	+0.30%	16.94	$4.27T	0.26%
AMZNAmazon.com, Inc.	$259.53	-1.11%	19.82	$2.79T	0.00%
METAMeta Platforms, Inc.	$742.96	+3.38%	27.93	$1.89T	0.28%

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is led by CEO Christopher T. Giordano, employs 4 people, headquartered in US, publicly traded since 1994.

Tenax Therapeutics, Inc. (TENX) stock trades at $1.83 with a market capitalization of $48.54M. The stock is valued at a price-to-earnings (P/E) ratio of -1.33, price-to-book of 0.89, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.31 and $19.40, and currently trades 90.6% below its 52-week high.

On profitability, Tenax Therapeutics, Inc. generates a return on equity (ROE) of -61.55%, return on capital employed of -60.40%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1182.62 +0.28% JNJ Johnson & Johnson $263.73 +0.88% ABBV AbbVie Inc. $281.04 +1.65% MRK Merck & Company, Inc. Common Stock (new) $145.45 -0.10% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.52 -0.21% NVS Novartis AG $143.84 +0.06% AZN AstraZeneca PLC $158.33 -0.55% TMO Thermo Fisher Scientific Inc $662.24 +0.64% AMGN Amgen Inc. $417.57 +0.65% GILD Gilead Sciences, Inc. $150.43 -0.49% ABT Abbott Laboratories $101.82 +2.23% NVO Novo Nordisk A/S $38.58 -0.16%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides